Due to the tumor heterogeneity and the limited clinical data, in our study, the METTL3 and ALKBH5 presented conflicting results in overall survival of stomach, liver and pancreatic cancer, further studies need to be performed to investigate the detailed mechanisms. This evidence concerns the gene METTL3 and neoplasm.